New drug fezolinetant tested for hot flash relief in everyday life

NCT ID NCT07602530

Recruiting now Symptom relief Sponsor: Astellas Pharma Europe Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows Canadian women in menopause who are prescribed fezolinetant by their own doctors for hot flashes and night sweats. Over 1 year, researchers track how well the drug improves symptoms, sleep, and well-being, as well as any side effects. It's a real-world look at how the treatment works outside of a controlled lab setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fezolinetant (VEOZAH)
What this could lead to: If successful, this study could confirm that fezolinetant effectively reduces hot flashes and night sweats in real-world settings, improving sleep and quality of life for menopausal women.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only includes Canadian women, and outcomes depend on patient reports, which can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HOT FLASHES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hot Flashes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HOT FLASHES

Contacts and locations

Locations

Site CA15001
RECRUITING

Prince Albert, Canada
Site CA15002
RECRUITING

Montreal, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.